← back to rankingIQV · IQVIA Holdings Inc.
Medical - Diagnostics & Research · mkt cap $30.1B · calls: Q1 FY2026 vs Q4 FY2025
64.0 conviction · conf-adj 64
conf 6/10 partial
enthusiasm:27.0 · trend:8 · quantifies:5 · impact:0 · under_radar:5 · credibility:12 · business_impact:4 · disruption:-6 · commitment:6 · confirmation:3
Enthusiasm latest 9 / prev 8 (rising)
Across Q4 FY2025 and Q1 FY2026, IQVIA frames AI/agentification as a durable demand tailwind—not a disruptor—anchored in proprietary healthcare data, regulatory-grade compliance, and embedded clinical/commercial workflows, with rising operational proof points (150+ → ~190–192 agents; 19/20 top pharma). Management quantifies deployment and adoption aggressively but does not attribute revenue, bookings, or margin to AI, and explicitly denies AI drove Q1 RDS book-to-bill weakness while claiming zero trial losses to AI tools. Credibility is stronger on moat-and-embedding narrative and named wins than on financial attribution; the thesis is strategically coherent but still largely qualitative at the P&L level.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $16.3B · net income $1.4B · net margin 8.3% · diluted EPS 7.84
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: 0.0% · next-FY EPS uplift: 0.0% · vs analysts: inline · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 6/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
192 AI agents / 64 use cases deployed (Q1 FY26)
engagement · soft | 192 agents; 64 use cases | Deployment count only; no $/agent, ARR, or revenue-per-use-case disclosed. Cannot convert a unit count to $ without inventing a per-agent economics figure. | | |
19 of top-20 pharma using IQVIA agents
engagement · soft | 19/20 (95%) | Adoption breadth, not a take-rate or wallet-share figure. No revenue per relationship disclosed; not sizeable to estimate. | | |
>150 agents/>30 use cases (Q4 FY25) -> >190/>50 recap; agents training on proprietary data >1yr; ~10yr AI at scale
other · soft | Q4->Q1 agents +28%, use cases +113%; decade tenure | Growth in deployment metrics and qualitative moat/tenure; no $ link (28% x $0 disclosed/agent = $0). No FY26 P&L increment. | | |
Trials lost to AI tools = exactly zero
other | 0 | Defensive retention claim: 0% of $16,310M = $0 incremental. Protects the franchise base; loss-prevention $ not quantified; adds no upside. | 0.0 | 0.0 |
Zero AI impact in bookings (Q1 FY26)
revenue | zero impact | Management explicit: AI-attributed bookings increment = $0 -> 100 x 0 / 16,310 = 0% rev -> $0 NI -> 0% EPS. No backlog converts to FY26 AI revenue. | 0.0 | 0.0 |
Commercial Solutions organic growth 5% (partly AI)
revenue · soft | 5% organic | Total-segment organic is computable on disclosed floor (Info=30% -> CS >= 0.30 x 16,310 = $4,893M; 5% x 4,893 = $244.65M = 1.50% of company). BUT management says only 'partly' AI and does not isolate the AI share. The AI-attributable slice requires an invented attribution split (Y assumed 30%), which the method prohibits -> AI portion unanchored. | | |
Info business ~30% of total, 'a little stronger' on AI data demand
revenue · soft | ~30% mix; LSD growth + AI tailwind | Info rev = 0.30 x 16,310 = $4,893M. Growth 'low single digits, a little stronger'; the AI increment ('a little stronger') is unquantified, so the AI-attributable revenue cannot be isolated without inventing a delta. | | |
Analytics & Consulting: highest growth in 3 years
revenue · soft | highest in 3yr (no number) | Unanchored superlative; no growth rate or $ for the AI-attributable slice. | | |
AI covers 80% of workflow tasks (20% SME)
productivity · soft | 80% | Capability/coverage ratio, not a saving. No opex base, FTE count, or labor-cost figure disclosed to multiply 80% against -> no after-tax saving computable. | | |
120+ obesity trials / 90,000+ patients (Duke)
other · soft | 120 trials; 90k patients | Cumulative operational scale credential; not AI revenue and not next-FY incremental. | | |
Assumptions: EPS denominator = adjusted net income ~$2,065M (consensus FY25 EPS $11.89 x ~173.5M sh), NOT depressed GAAP NI $1,360M/$7.84, to match consensus basis and avoid a thin-base EPS% artifact. Revenue base FY2025 actual $16,310M. Tax 21%; implied current net margin ~8.34% (= 1,360/16,310) would be the default incremental margin had any AI revenue been anchored (moot). IQVIA is an adopter, no supplier/compute-sales side. Phasing N/A: no multi-year AI $ target disclosed. The total Commercial Solutions 5% organic is computable on the disclosed Info=30% floor (~1.5% of company revenue), but the AI-attributable share of it is unquantified by management ('partly') and is not estimated rather than invented.
Top line: Effectively nil quantifiable AI top-line. Management deployed 192 agents/64 use cases with 19/20 top pharma adopting, but explicitly stated 'zero impact from AI in bookings' and 'trials lost to AI = exactly zero.' The only anchored AI-to-financials figures are zeros (defensive). Real growth exists (Commercial 5% organic, Analytics 'highest in 3yr', Info 'a little stronger'), but the AI-attributable slice is not isolated by management; sizing it requires an invented attribution split, so no defensible incremental AI rev% on the $16.31B base survives. AI is framed as a demand tailwind and franchise defense, not a quantified driver.
Bottom line: No quantifiable EPS uplift. The 80%-of-tasks automation claim has no disclosed opex/FTE/labor base to multiply against, so no after-tax saving is computable (would otherwise be sized vs adjusted ~$2,065M net income, not the thin GAAP $1,360M which inflates any %). With zero anchored AI revenue and zero anchored cost-saving figures, est_eps_uplift_pct = 0.0.
Consensus already builds in revenue $16.18B->$17.28B and adj EPS $11.89->$12.80 (~+7%) on normal CRO/commercial recovery. Management attributes 0% of bookings to AI, so the program adds nothing identifiable ABOVE consensus. The defensive 'zero trials lost' framing protects the base but creates no upside vs trajectory -> AI angle is fully priced in / immaterial to the estimate.
MODEL CONSENSUS (impact)
partial
Agree all named claims are defensive/unanchored; conflict only on whether to estimate an AI slice of disclosed organic growth. Chose conservative no-invention path.
Conflicts reconciled
- est_rev_uplift_pct: X=0.0 vs Y=0.45 -> used 0.0 because Y's figure rests on an invented 30% AI-attribution split of organic growth, which the method prohibits ('do not invent a number'); total organic is computable but not AI-attributable
- est_eps_uplift_pct: X=0.0 vs Y=0.3 -> used 0.0 for same reason
- Commercial Solutions/Info rows: X=soft/null vs Y=hard 0.45/0.30 & 0.30/0.20 -> used soft/null; segment $ is anchored but the AI share is unquantified
- supplier_rev_uplift_pct: X=null vs Y=0 -> used null (no supplier side exists for an adopter)
- confidence: X=7 -> lowered to 6 due to the material aggregate conflict
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | 0.0 | – |
| EPS uplift % | 0.0 | – |
| Priced in | high | – |
| vs analysts | inline | – |
| Confidence | 7 | – |
| Top line | Effectively nil quantifiable. Management deployed 192 agents/64 use cases with 19/20 top pharma adopting, but explicitly stated 'zero impact from AI in our bookings' and 'trials lost to AI = exactly zero.' The only anchored AI-to-financials figures are zeros (defensive). The Commercial 5% organic / Analytics 'highest in 3yr' / Info 'a little stronger' references are real growth but the AI-attributable slice is not isolated, so none converts to a defensible incremental rev% on the $16.31B base. AI is framed as a demand tailwind and franchise defense, not a quantified top-line driver. | – |
| Bottom line | No quantifiable EPS uplift. The 80%-of-tasks automation claim has no disclosed opex/FTE/labor base to multiply against, so no after-tax saving is computable (would otherwise be sized vs the adjusted ~$2.065B net income, not the thin GAAP $1.36B which would inflate any %). With zero anchored revenue and zero anchored cost-saving figures, est_eps_uplift_pct = 0.0. | – |
| Reasoning | Consensus already builds in rev $16.18B->$17.28B FY25->FY26 (+6.80%) and adj EPS $11.89->$12.80 (+7.65%), driven by normal CRO/commercial recovery. Management itself attributes 0% of bookings to AI, so the AI program adds nothing identifiable ABOVE the ~6.8%/7.6% consensus already assumes. The defensive 'zero trials lost' framing protects the base but does not create upside vs the trajectory -> the AI angle is fully priced in / immaterial to the estimate. | – |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
AI agents deployed: 192 (to date, Q1 FY2026, both)
“To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses.”
AI agent use cases: 64 (to date, Q1 FY2026, both)
“To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses.”
Top-20 pharma adoption of IQVIA agents: 19 of the top twenty (to date, Q1 FY2026, topline)
“Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows”
AI agents deployed (closing recap): more than 190 (Q1 FY2026, both)
“more than 190 agents deployed covering over 50 use cases across Commercial Solutions and RDS businesses, with 19 out of the top 20 pharma companies already using our agents”
AI agents deployed: over 150 (to date, Q4 FY2025, both)
“And to date, we've deployed over 150 agents covering over 30 use cases across the business, clinical and commercial.”
AI agent use cases: over 30 (to date, Q4 FY2025, both)
“we've deployed over 150 agents covering over 30 use cases across the business, clinical and commercial.”
Agent training on proprietary data: over a year (as of Q4 FY2025, both)
“Bear in mind, our agents have been training on our data assets for over a year now.”
AI integration tenure: nearly a decade (historical through Q1 FY2026, both)
“We have been integrating AI into our operations and solutions at scale for nearly a decade.”
Trials lost to AI competitors/tools: exactly zero (Q1 FY2026 bookings, topline)
“The number of trials that we lost to anyone using any AI tool is exactly zero.”
AI-attributed bookings impact: zero impact (Q1 FY2026, topline)
“there is zero impact from AI in our bookings”
Analytics and Consulting growth vs. prior peaks: highest growth we have seen in three years (Q1 FY2026, topline)
“Analytics and Consulting, which had the highest growth we have seen in three years”
Commercial Solutions organic growth: 5% (Q1 FY2026 (organic; management links partly to AI demand), topline)
“our organic growth rate in Commercial Solutions this quarter was 5%”
Commercial Info segment share: about 30% (Q1 FY2026 mix commentary, topline)
“our Info business is about 30% of the total and continues to grow low single digits, a little stronger given more demand for data that our AI agents create”
Automation share of workflow tasks (general AI claim): 80% (Q4 FY2025, bottomline)
“Most of what AI does by the way, it covers 80% of what needs to be done. But you still not need to have someone with the subject matter expertise to complete the remaining 20%.”
Obesity trial experience (AI-adjacent operational scale cited with Duke partnership): more than 120 obesity trials; more than 90,000 patients (cumulative, cited Q1 FY2026, topline)
“having supported more than 120 obesity trials and enrolled more than 90,000 patients”
PAST (realized)
- Q1 FY2026 — Ari Bousbib: "We have been integrating AI into our operations and solutions at scale for nearly a decade."
- Q1 FY2026 — Ari Bousbib: "We have been doing this for years through protocol optimization, site identification, and operational risk mitigation" (RDS AI for trial design/execution).
- Q4 FY2025 — Ari Bousbib: "we started on this AI journey quite a while ago" and NVIDIA partnership "over a year" with agents built into clinical and commercial workflows.
- Q4 FY2025 — Ari Bousbib: "our agents have been training on our data assets for over a year now."
- Q4 FY2025 — Ari Bousbib: "AI identification is a positive, has been a positive" (past and present).
- Q4 FY2025 — Ari Bousbib: Investments in cloud and AI/ML referenced back to 2019 Investor Day (in response to Justin Bowers).
CURRENT (now)
- Q1 FY2026 — 192 agents deployed, 64 use cases; 19 of top 20 pharma using IQVIA agents in workflows.
- Q1 FY2026 — iqvia.ai agentic AI portal/marketplace unveiled at NVIDIA GTC.
- Q1 FY2026 — Commercial pipelines at record levels; AI linked to more client questions and demand for differentiated AI capabilities.
- Q1 FY2026 — Analytics and Consulting: strongest growth in three years; record pipeline; AI disruption fears "tailwind" already visible.
- Q1 FY2026 — Clients selecting IQVIA for AI-ready data foundations; multiple Q1 contract wins explicitly AI-driven (commercial reporting, safety/PV, full-service trials, etc.).
- Q1 FY2026 — Zero trials lost to any AI tool; zero AI impact on Q1 bookings metric per management.
- Q4 FY2025 — 150+ agents, 30+ use cases deployed; AWS preferred agentic cloud partner; Everest Group #1 generative AI leadership among CROs.
- Q4 FY2025 — Commercial demand for AI-driven innovations "gaining momentum," especially large pharma; DAS "AI-ready data" in demand.
- Q4 FY2025 — Clinical wins citing AI-driven planning, recruiting, randomization, drug supply optimization.
FORWARD (guidance)
- Q1 FY2026 — Ari Bousbib: "We feel confident that the tailwind will continue" (AI disruption concerns as demand driver).
- Q1 FY2026 — iqvia.ai enables visibility to broader AI portfolio "to support future solution adoption."
- Q1 FY2026 — Large pharma to increase pipeline molecules using AI target identification → more trials and CRO demand; some clients evaluating capacity ramp for more targets (4–5 year LOE window).
- Q1 FY2026 — Commercial lines including Analytics/Consulting, Tech, Engagement "will grow mid to high single digits going forward" with AI agents.
- Q1 FY2026 — Duke CR obesity collaboration designed to accelerate start-up and execution; "significant pipeline of opportunities and a few wins in the second quarter."
- Q4 FY2025 — Ari Bousbib: AI/agentification "will continue to be a positive for us"; increasing demand for next-generation information management; AWS partnership to enable faster delivery of treatments.
- Q4 FY2025 — Ari Bousbib: Discovery-stage client AI could theoretically mean fewer trials, but clients say they will do more trials; no change in demand dynamics expected.
TRACK RECORD — PROMISE vs DELIVERY
92/100 track record delivers 6 calls reviewed
Across six calls IQVIA rarely gave dated, numeric AI targets; the main ones were Q1 FY2025 use-case milestones (12 by Q2, 40 by year-end), which later calls imply were met or exceeded. They emphasize deployment scale and client adoption rather than AI revenue KPIs.
Scale agentic AI from 3 use cases to 12 use cases by end of Q2 FY2025 — promised Q1 FY2025
delivered No Q2 count on the call, but Q3 FY2025 reported ~25 use cases (90 agents in development), clearly above 12 by mid-H2 FY2025.
Expand agentic AI to 40 use cases by end of FY2025 — promised Q1 FY2025
delivered Q3 had 25 use cases; Q1 FY2026 reported 64 use cases and 192 agents deployed—well above 40 after the Dec 2025 deadline (Q4 did not restate the exact year-end figure).
Move 20+ NVIDIA-backed industry AI agents into production across commercial, real-world, and R&DS — promised Q1 FY2025
delivered Treated as a near-term deployment baseline in the same call; Q3 cited ~90 agents in development and Q1 FY2026 cited 192 agents deployed with 19/20 top pharma using agents.
PRICED-IN (REFINED)
MEDIUMEst. revisions rising · Fwd P/E 15.2 · EV/Sales 1.8x
AI claim maps to Technology And Analytics Solutions, Research And Development Solutions
Analyst sentiment is migrating up (holds fell from 5 to 2 since Jan 2026 while buys held ~17) and near-term price targets rose (lastQuarterAvg 206.67 to lastMonthAvg 217.5), with consensus baking in mid-single-digit revenue and ~8–11% EPS growth through 2027—signals that some AI/efficiency upside is already in estimates. Valuation is not stretched (fwd P/E ~15.2, EV/Sales ~1.8), so the market is not fully paying a premium despite rising revisions. AI claims map most plausibly to Technology And Analytics Solutions and secondarily Research And Development Solutions, not contract sales. Mixed picture: rising revisions increase priced-in risk, but reasonable multiples leave room if AI accelerates TAS/RDS faster than consensus—hence medium, not high.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
8Q4 FY20245Q1 FY20259Q2 FY20258Q3 FY20258Q4 FY20259Q1 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
After a macro-heavy Q1 dip, IQVIA tied AI to NVIDIA/AWS, agent scale, top-pharma adoption, and commercial demand.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
6/10 qualitative impact moderate medium-term · mixed evidence
Where AI matters: TAS/RDS agentic solutions on proprietary healthcare data
192 agents, 64 use cases, and 19/20 top-pharma adoption are real embedded product scale, but management attributes zero bookings impact and no isolated AI revenue or margin—upside is strategic demand and franchise defense, not yet a quantified P&L driver.
Caveats: Zero management-attributed AI bookings or EPS uplift despite aggressive deployment metrics; Consulting and full-service RDS remain exposed to billable-hour and pass-through deflation as clients internalize agents; Strong AI narrative may run ahead of financial proof—commercial acceleration is only partly tied to AI
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 4/10
GenAI can compress analytics/consulting hours and trial-efficiency billables, but regulated execution, compliance-grade data, and client AI-driven target discovery (more trials) offset commoditization of the core CRO/data franchise.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $298M · beta 1.179 · px $180.64
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 7/10 committed.
INSIDERS selling 1 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 123 new / 195 closed positions; 540 increased / 396 reduced; institutional ownership -2.83pp; -65 net 13F holders
MGMT LANGUAGE 7/10 committed Substantial AI section with deployed-agent counts and client adoption; occasional soft phrasing on demand drivers and future adoption.
commit “To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses.”
commit “We already function as an AI-native company in life sciences.”
commit “Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows”
VERBATIM AI QUOTES
“We feel good about demand on the commercial side with pipelines growing to record levels, and we think AI has something to do with it. AI is causing our clients to have more questions. It is causing them to increase their demand for IQVIA Holdings Inc.'s differentiated AI capabilities and for the innovation we are embedding across our commercial offerings.”
— Ari Bousbib, Q1 FY2026
“So why was our book-to-bill ratio 1.04 in the quarter despite solid service fee bookings growth and normal cancellations, and no, AI has nothing to do with it?”
— Ari Bousbib, Q1 FY2026
“A brief update on AI: IQVIA Holdings Inc.'s AI solutions are built on our unparalleled proprietary data foundation, best-in-class compliance with the privacy, regulatory, and integrity standards healthcare-grade AI demands, and are connected to our deep life sciences and healthcare expertise. We have been integrating AI into our operations and solutions at scale for nearly a decade. It is part of who we are and what we do. We already function as an AI-native company in life sciences.”
— Ari Bousbib, Q1 FY2026
“A few weeks ago, we unveiled iqvia.ai at NVIDIA's GTC conference. This is our agentic AI portal and marketplace purpose-built for life sciences. It provides clients a single access point to their purchased IQVIA Holdings Inc. AI solutions, enabling centralized control with their internal user base, while also enabling visibility to a broader AI portfolio to support future solution adoption.”
— Ari Bousbib, Q1 FY2026
“Our deployment of highly specialized life sciences industry AI agents is progressing as planned. To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses. Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows, underscoring broad industry trust in our AI capabilities.”
— Ari Bousbib, Q1 FY2026
“Switching to client activity in Commercial Solutions, this quarter we saw clients increasingly selecting IQVIA Holdings Inc. to build AI-ready data foundations, which facilitate the incorporation of AI agents, including our agents, into their workflows.”
— Ari Bousbib, Q1 FY2026
“Turning to R&D Solutions, our strategy has been to leverage our AI solutions to optimize trial design and execution to reduce timelines for our clients. We have been doing this for years through protocol optimization, site identification, and operational risk mitigation, and we are taking this to the next level with AI agents, which lead to much faster study execution and increased quality by reducing errors and rework.”
— Ari Bousbib, Q1 FY2026
“For an EDP, we are delivering a global late-stage clinical program that integrates clinical and laboratory services within a single operating model, with agentified analytics embedded across site feasibility and selection, enrollment, and performance forecasting.”
— Ari Bousbib, Q1 FY2026
“We continue to make very strong progress in the deployment of highly specialized life sciences industry AI agents, with more than 190 agents deployed covering over 50 use cases across Commercial Solutions and RDS businesses, with 19 out of the top 20 pharma companies already using our agents in some of their workflows.”
— Michael Fedock, Q1 FY2026
“Again, there is zero impact from AI in our bookings. The number of trials that we lost to anyone using any AI tool is exactly zero.”
— Ari Bousbib, Q1 FY2026
“On the clinical side, our AI work focuses on creating efficiency and improved execution to reduce timelines. On the commercial side, we are focused on innovation—creating new offerings—and those are gaining traction. Customers are dealing with massive amounts of data from us, from third parties, and generated by their own operations, and with disparate legacy systems. AI agentification enables clients to bypass and leapfrog systems and multiple vendors and data sources, analyze information much faster, derive insights, and make decisions at much higher speed. Our agents are healthcare-grade AI, tailor-made for regulatory requirements.”
— Ari Bousbib, Q1 FY2026
“Concerns that AI would replace services are unfounded; quite the opposite, it creates new demand. The part of our commercial business theoretically most vulnerable to AI disruption—Analytics and Consulting—actually has a record pipeline and very strong growth, the best in three years, and we see this continuing.”
— Ari Bousbib, Q1 FY2026
“Our Info business is about 30% of the total and continues to grow low single digits, a little stronger given more demand for data that our AI agents create.”
— Ari Bousbib, Q1 FY2026
“The AI disruption concerns are actually a tailwind for our business, and we are seeing it already. We feel confident that the tailwind will continue.”
— Ari Bousbib, Q1 FY2026
“Looking forward, large pharma clients tell us they plan to increase the number of molecules in their pipeline because they are using AI to identify more targets, most of which is at the discovery stage. That will increase the number of trials and the number of assets pursued, which in turn increases demand for CRO services, not the opposite.”
— Ari Bousbib, Q1 FY2026
“Seeing great demand among the large and midsized pharma clients for our DAS solution does data as a service, which provides AI-ready data as a single harmonized source simplifying customers' data management and building a strong foundation for AI analytics.”
— Ari Bousbib, Q4 FY2025
“We announced the strategic collaboration with Amazon Web Services namely AWS as our preferred agentic car provider to accelerate the industry's digital transformation. With the world's largest pharmaceutical companies already relying on IQVIA and AWS. We believe this partnership remains AI more revenue available across life sciences, medical affairs and health care analytics and enable faster delivery of life-saving treatments to patients worldwide.”
— Ari Bousbib, Q4 FY2025
“IQVIA was recognized by Everest Group for our AI leadership, the only clinical research organization to receive the #1 ranking for generative AI leadership in life sciences.”
— Ari Bousbib, Q4 FY2025
“You will recall that we started on this AI journey quite a while ago, and specifically, a little more than a year ago, we announced a partnership with NVIDIA, which with whom we have been working for over a year to build agents into our workflows, both in clinical and commercial, and we have made significant progress to date.”
— Ari Bousbib, Q4 FY2025
“In commercial, demand for our AI-driven innovations is gaining momentum with our clients, especially in large pharma.”
— Ari Bousbib, Q4 FY2025
“There are 3 requirements for AI agents. Number one, significant ready-to-consume data ingredients at scale. Number two, domain expertise. And number three, technology, meaning the AI tools everybody talks about with French names, and the processing capability to enable this AI agents to work.”
— Ari Bousbib, Q4 FY2025
“That is it in what we've been calling with our clients, health care-grade AI. And this is why our clients trust us to work with them on their own AI journey.”
— Ari Bousbib, Q4 FY2025
“Bear in mind, our agents have been training on our data assets for over a year now. And to date, we've deployed over 150 agents covering over 30 use cases across the business, clinical and commercial.”
— Ari Bousbib, Q4 FY2025
“Overall, I would say AI identification is a positive for our business across both clinical and commercial, and I understand it's hard to distinguish between us and other CROs, us and other information services provider.”
— Ari Bousbib, Q4 FY2025
“Our proprietary data assets, which are not stopable by horizontal AI models are more valuable than ever actually.”
— Ari Bousbib, Q4 FY2025
“AI identification is a positive, has been a positive, will continue to be a positive for us.”
— Ari Bousbib, Q4 FY2025
“AI delivers the most value when it's embedded in existing workflows. Why should you build the new wheel if the existing one works and you can simply optimize it. Most of what AI does by the way, it covers 80% of what needs to be done. But you still not need to have someone with the subject matter expertise to complete the remaining 20%.”
— Ari Bousbib, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Leerink Partners (unnamed)): Services vs. pass-through bookings and margin progression on full-service RDS wins—not framed as AI, but management addressed AI in the answer.
A: Ari Bousbib: "Again, there is zero impact from AI in our bookings. The number of trials that we lost to anyone using any AI tool is exactly zero. And, again, no impact on margins whatsoever from the unusually low pass-throughs in the bookings this quarter."
Q (Q1 FY2026, Barclays (unnamed)): Drivers of Commercial Solutions upside; mix of recurring vs. discretionary revenue.
A: Ari Bousbib tied acceleration to AI on commercial: clinical AI for efficiency/timeline reduction; commercial AI agentification to leapfrog legacy systems; "Concerns that AI would replace services are unfounded; quite the opposite, it creates new demand"; Analytics and Consulting has "record pipeline and very strong growth, the best in three years"; Info ~30% of commercial with "more demand for data that our AI agents create"; Patient Solutions double-digit growth; other commercial lines "supplemented with AI agents" growing mid to high single digits.
Q (Q1 FY2026, Shlomo Rosenbaum, Stifel): Where is growth accelerating vs. stabilizing; is performance indicative of market growth or improving win rates?
A: Ari Bousbib: "The AI disruption concerns are actually a tailwind for our business, and we are seeing it already. We feel confident that the tailwind will continue." Large pharma plans more pipeline molecules "because they are using AI to identify more targets" (mostly discovery), which "will increase the number of trials" and CRO demand; some clients ask what it takes to ramp capacity for more targets.
Q (Q4 FY2025, Shlomo Rosenbaum, Stifel): Concerns about AI disrupting established businesses; why IQVIA is insulated; why AI is enabling vs. a risk.
A: Ari Bousbib: Three requirements for AI agents—data at scale, domain expertise, technology (buyable). Proprietary, regulated, dynamic healthcare data cannot be replicated from the web. Healthcare-grade AI needs deep domain expertise. "AI identification is a positive for our business across both clinical and commercial." Over 150 agents, 30+ use cases; agents trained on IQVIA data 1+ year. Per-task model selection (OpenAI, Claude, own tools). Scale across 10,000+ clients justifies investment. Some lower-level consulting may be displaced but demand rises for new offerings including next-gen information management.
Q (Q4 FY2025, Justin Bowers, Deutsche Bank): Is AI an opportunity or risk; accretive, neutral, or decremental to segment growth (especially RDS)? Improving RDS environment and path to ~1.2 book-to-bill in 2026?
A: Ari Bousbib: "AI justification is a positive, has been a positive, will continue to be a positive for us." Largest proprietary healthcare data assets; industry expertise not replaceable by generic LLMs; clients' AI initiatives enabled by IQVIA data/services/workflows; AI embedded in workflows, ~80% automated but 20% needs SME; does not project book-to-bill but demand metrics (pipeline, RFP flow) remain strong.
Q (Q4 FY2025, Elizabeth Anderson, Evercore ISI): Pfizer and others using AI for trial efficiency—any change in large-pharma behavior (e.g., fewer FSP seats)? Anything different in profitability cadence in 2026?
A: Ari Bousbib: No change; IQVIA built on trial-efficiency innovation; large pharma works with IQVIA on AI agents for clinical efficiency. Client mentions of AI are "99%" discovery-stage target identification upstream—not IQVIA's business; if anything, "more trials"; "no change in demand dynamics"; "only see opportunities for productivity improvements"; partnership model stable and growing.